Sanofi India Limited has informed the Exchange about Retirement of Ms. Renee Amonkar (DIN: 10335917) as the Whole-time Director and Site Director - Goa
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanofi India reported Q1 FY26 revenue from operations of ₹4,063 million, down about 12% from ₹4,635 million in Q1 FY25, while profit after tax from continuing operations rose slightly to ₹695 million from ₹682 million. The board approved unaudited results for the quarter and half-year ended 30 June 2025. Ms. Renee Amonkar, Whole-time Director and Site Director – Goa, will retire effective 11 August 2025 and will also cease to be a Key Managerial Personnel. Mr. Mahadev Gawade (ex-Sandoz India, 20+ years in pharma manufacturing and logistics) has been appointed as her replacement for a three-year term. Additionally, the company disclosed a subsequent promotion and distribution agreement with Emcure Pharmaceuticals for its Oral Anti-diabetic (OAD) portfolio.
The director transition looks orderly with a like-for-like internal-style replacement, so governance continuity should not be a concern for shareholders. The sharp revenue drop YoY is a watch-point, though margins held up reasonably well. The Emcure distribution deal could help Sanofi India extend reach for its diabetes brands without building its own field force.